Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1993 Jan;52(1):54–57. doi: 10.1136/ard.52.1.54

Paget's disease of bone treated with a five day course of oral tiludronate.

J Y Reginster 1, M P Lecart 1, R Deroisy 1, D Ethgen 1, B Zegels 1, P Franchimont 1
PMCID: PMC1004956  PMID: 8427515

Abstract

Chloro-4-phenyl thiomethylene bisphosphonate (tiludronate) is a new drug which can be used as an inhibitor of bone resorption. As it remains in bone for a long time, and as mineralisation defects have only been seen at doses much higher than those required to decrease osteoclastic activity, it could be given at high doses over a short period of time. Eighteen patients with Paget's disease of bone were randomly allocated to three therapeutic groups receiving respectively 600, 800, and 1200 mg/day tiludronate for five days. Serum alkaline phosphatase activity and the urinary hydroxyproline/creatinine ratio were quickly and drastically reduced in all three groups. A significant reduction of serum alkaline phosphatases and the hydroxyproline/creatinine ratio was still present six months after the five day therapeutic course, reflecting a sustained activity of tiludronate even after stopping treatment. Dose dependent short and long term reductions of bone turnover rate were observed. Biochemical assessment of haematological, renal, or hepatic tolerance did not show any toxicity of tiludronate. Fifty per cent of patients treated by a dose of 1200 mg/day reported gastrointestinal disturbances, however, making this dosage unsuitable for clinical practice.

Full text

PDF
54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S., Salvagno G., Guarrera G., Montesanti F., Garavelli S., Rosini S., Lo Cascio V. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int. 1986 Oct;39(4):226–229. doi: 10.1007/BF02555208. [DOI] [PubMed] [Google Scholar]
  2. Alexandre C., Meunier P. J., Edouard C., Khairi R. A., Johnston C. C. Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone. Metab Bone Dis Relat Res. 1981;3(4-5):309–315. doi: 10.1016/0221-8747(81)90047-3. [DOI] [PubMed] [Google Scholar]
  3. Atkins R. M., Yates A. J., Gray R. E., Urwin G. H., Hamdy N. A., Beneton M. N., Rosini S., Kanis J. A. Aminohexane diphosphonate in the treatment of Paget's disease of bone. J Bone Miner Res. 1987 Aug;2(4):273–279. doi: 10.1002/jbmr.5650020403. [DOI] [PubMed] [Google Scholar]
  4. Audran M., Clochon P., Etghen D., Mazieres B., Renier J. C. Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate. Clin Rheumatol. 1989 Mar;8(1):71–79. doi: 10.1007/BF02031073. [DOI] [PubMed] [Google Scholar]
  5. Chapuy M. C., Charhon S. A., Meunier P. J. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate. Metab Bone Dis Relat Res. 1983;4(6):325–328. [PubMed] [Google Scholar]
  6. Emonds-Alt X., Brelière J. C., Roncucci R. Effects of 1-hydroxyethylidene-1,1 bisphosphonate and (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial cells. Biochem Pharmacol. 1985 Nov 15;34(22):4043–4049. doi: 10.1016/0006-2952(85)90385-5. [DOI] [PubMed] [Google Scholar]
  7. Frijlink W. B., Bijvoet O. L., te Velde J., Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):799–803. doi: 10.1016/s0140-6736(79)91318-7. [DOI] [PubMed] [Google Scholar]
  8. Gibbs C. J., Aaron J. E., Peacock M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J (Clin Res Ed) 1986 May 10;292(6530):1227–1229. doi: 10.1136/bmj.292.6530.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harinck H. I., Bijvoet O. L., Blanksma H. J., Dahlinghaus-Nienhuys P. J. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop Relat Res. 1987 Apr;(217):79–98. [PubMed] [Google Scholar]
  10. Kanis J. A., Gray R. E. Long-term follow-up observations on treatment in Paget's disease of bone. Clin Orthop Relat Res. 1987 Apr;(217):99–125. [PubMed] [Google Scholar]
  11. Kanis J. A., Urwin G. H., Gray R. E., Beneton M. N., McCloskey E. V., Hamdy N. A., Murray S. A. Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med. 1987 Feb 23;82(2A):55–70. doi: 10.1016/0002-9343(87)90488-8. [DOI] [PubMed] [Google Scholar]
  12. Meunier P. J., Chapuy M. C., Alexandre C., Bressot C., Edouard C., Vignon C., Mathieu L., Trechsel U. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet. 1979 Sep 8;2(8141):489–492. doi: 10.1016/s0140-6736(79)91551-4. [DOI] [PubMed] [Google Scholar]
  13. O'Doherty D. P., Bickerstaff D. R., McCloskey E. V., Hamdy N. A., Beneton M. N., Harris S., Mian M., Kanis J. A. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res. 1990 May;5(5):483–491. doi: 10.1002/jbmr.5650050510. [DOI] [PubMed] [Google Scholar]
  14. Reginster J. Y., Gritten C., Diverse P., Hauwaert P. C., Crielaard J. M., Halleux R., Franchimont P. Traitement de la maladie de Paget par l'étidronate disodique (EHDP) à faible dose (5 mg/kg par jour). Apparition de leucopénies transitoires réversibles suspectes. Rev Rhum Mal Osteoartic. 1985 Mar;52(3):145–150. [PubMed] [Google Scholar]
  15. Reginster J. Y., Jeugmans-Huynen A. M., Albert A., Denis D., Deroisy R., Lecart M. P., Fontaine M. A., Collette J., Franchimont P. Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone. 1988;9(6):349–354. doi: 10.1016/8756-3282(88)90115-9. [DOI] [PubMed] [Google Scholar]
  16. Reginster J. Y., Lecart M. P., Deroisy R., Sarlet N., Denis D., Ethgen D., Collette J., Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23;2(8678-8679):1469–1471. doi: 10.1016/s0140-6736(89)92927-9. [DOI] [PubMed] [Google Scholar]
  17. Thiébaud D., Jaeger P., Burckhardt P. Paget's disease of bone treated in five days with AHPrBP (APD) per Os. J Bone Miner Res. 1987 Feb;2(1):45–52. doi: 10.1002/jbmr.5650020108. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES